Q1 EPS Estimate for DiaMedica Therapeutics Raised by Analyst

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) – Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for DiaMedica Therapeutics in a report released on Wednesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.17) per share for the quarter, up from their previous estimate of ($0.18). The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.75) EPS and FY2028 earnings at ($0.35) EPS.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The company had revenue of ($0.03) million during the quarter, compared to the consensus estimate of $13.50 million.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, DiaMedica Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Price Performance

Shares of DMAC opened at $6.48 on Friday. DiaMedica Therapeutics has a 12 month low of $3.19 and a 12 month high of $10.42. The stock has a fifty day moving average price of $7.80 and a 200 day moving average price of $7.64. The company has a market cap of $349.14 million, a P/E ratio of -9.26 and a beta of 1.16.

Institutional Investors Weigh In On DiaMedica Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in DiaMedica Therapeutics in the third quarter worth approximately $27,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of DiaMedica Therapeutics during the 4th quarter valued at $29,000. Bank of America Corp DE raised its stake in shares of DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after buying an additional 8,274 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth $34,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of DiaMedica Therapeutics in the second quarter valued at $49,000. Institutional investors own 10.12% of the company’s stock.

More DiaMedica Therapeutics News

Here are the key news stories impacting DiaMedica Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed expected quarterly losses across 2026 — raising Q1 to ($0.17), Q2 to ($0.18), Q3 to ($0.19) and Q4 to ($0.21) EPS (less negative than prior forecasts). These revisions narrow projected losses for FY2026 and FY2027 (both raised to ($0.75)). The smaller-than-expected losses improve the earnings trajectory and are a near‑term positive for the stock.
• Positive Sentiment: HC Wainwright also raised its FY2028 estimate to ($0.35) from ($0.37) and issued a long‑term profitable outlook for FY2030 at $0.56 EPS — signaling a path to sustained profitability over the next few years, which supports a higher valuation multiple for this biotech developer.
• Neutral Sentiment: Recent Q4 2025 earnings call transcript is available for investors who want detail on management commentary, clinical progress and cash runway; the call itself didn’t contain a separate headline announcement beyond the reported results. Earnings Call Transcript
• Negative Sentiment: HC Wainwright slightly lowered its FY2029 EPS view to $0.14 from $0.15 — a small downward revision that may temper enthusiasm among investors focused on nearer‑term upside to consensus large positive numbers in later years.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.